HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Radiation reduction trial aims to boost quality of life for head and neck cancer survivors
Disease control Recruiting nowThis study looks at whether people with advanced head and neck cancer who had a good response to chemo-immunotherapy before surgery can safely avoid low-dose radiation to the neck afterward. The goal is to maintain cancer control while reducing side effects and improving quality …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 16, 2026 22:49 UTC
-
New drug EXS74539 enters early human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:51 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental oral drug called VMD-928, given alone or with pembrolizumab, in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug can shrink tumors. About 242 peop…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: VM Oncology, LLC • Aim: Disease control
Last updated Jun 15, 2026 19:09 UTC
-
Second radiation plus drug shows promise for tough head and neck cancer
Disease control Recruiting nowThis early-stage study tests a combination of a second round of radiation and a drug called chidamide for people whose head and neck cancer has come back after previous radiation. The main goal is to find a safe dose and see if the treatment can shrink tumors. Only 6 adults aged …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Can a sixth day of radiation beat cancer recurrence?
Disease control Recruiting nowThis study compares two radiotherapy schedules for people with head and neck cancer who begin radiation more than 6 weeks after surgery. One group gets standard treatment (5 days a week), the other gets an accelerated schedule (6 days a week). The goal is to see if the faster sch…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 15, 2026 19:02 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 15, 2026 19:01 UTC
-
New drug combo aims to control advanced cancers
Disease control Recruiting nowThis early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: LG Chem • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New drug STRO-004 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called STRO-004 in adults with advanced solid tumors that have not responded to other treatments. The trial has three parts: finding a safe dose of STRO-004 alone, testing that dose in more people, and combining STRO-004 with another drug (pe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New drug duo aims to shrink head and neck tumors in first-line trial
Disease control Recruiting nowThis study tests whether adding an experimental drug (fianlimab) to a standard immunotherapy (cemiplimab) works better than the standard drug alone for people with advanced head and neck cancer that has come back or spread. About 120 adults whose tumors have a specific marker (PD…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 10, 2026 13:27 UTC
-
New drug EPI-326 targets tough cancers in early human trial
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung cancer (with a specific EGFR gene change) or head/neck cancer. The main goal is to find a safe dose and check for side effects. Researchers will also see if the drug helps shrink tumors.
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New hope for Hard-to-Treat cancers: experimental drug MT-4561 enters human trials
Disease control Recruiting nowThis study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have already tried at least one other treatment. The main goals are to find a safe dose and see if the drug can shrink tumors. About 27 adults w…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1, PHASE2 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New drug duo aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests two drugs, ficerafusp alfa and pembrolizumab, given before surgery to people with advanced head and neck cancer that can be removed. The goal is to see if the combination can shrink tumors and improve outcomes. About 32 participants will receive the treat…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 03, 2026 12:03 UTC
-
New drug duo shows promise against head and neck cancer in early trial
Disease control Recruiting nowThis early-stage study is testing whether a new drug (GV20-0251) combined with an immunotherapy (sintilimab) is safe and can shrink tumors before surgery in adults with head and neck cancer. Nine participants will receive two cycles of the drug combo, then have surgery to remove …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 01, 2026 18:07 UTC
-
New scan may spot hidden cancer cells before surgery
Diagnosis Recruiting nowThis study is testing a new type of PET/CT scan that targets specific cells around tumors to see if it can find early signs of cancer spread to lymph nodes in people with head and neck cancer. About 20 adults scheduled for surgery will receive this scan before their operation. Th…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: PHASE2 • Sponsor: John O. Prior • Aim: Diagnosis
Last updated Jun 15, 2026 19:02 UTC
-
App-Based monitoring may prevent weight loss in head and neck cancer patients
Symptom relief Recruiting nowThis study tests whether using a smartphone app to regularly report symptoms can help doctors catch problems early and reduce weight loss in head and neck cancer patients undergoing curative radiation or chemoradiation. About 192 adults will be enrolled. The goal is to see if rem…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Symptom relief
Last updated Jun 15, 2026 19:08 UTC
-
Scientists gather key materials to create personalized cell therapies for Hard-to-Treat cancers
Knowledge-focused Recruiting nowThis study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand which cancers might respond to a future CAR T-cell therapy and to store participants' own immune cells for potential …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:02 UTC